Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.

@article{Brooks2016EarlyTC,
  title={Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.},
  author={Jill M. Brooks and Heather M Long and Rose J Tierney and Claire D Shannon-Lowe and Alison M. Leese and Martin A Fitzpatrick and Graham R. Taylor and Alan B. Rickinson},
  journal={PLoS pathogens},
  year={2016},
  volume={12 4},
  pages={
          e1005549
        }
}
Epstein-Barr virus, a B-lymphotropic herpesvirus, is the cause of infectious mononucleosis, has strong aetiologic links with several malignancies and has been implicated in certain autoimmune diseases. Efforts to develop a prophylactic vaccine to prevent or reduce EBV-associated disease have, to date, focused on the induction of neutralising antibody responses. However, such vaccines might be further improved by inducing T cell responses capable of recognising and killing recently-infected B… CONTINUE READING
5
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell 162: 1090–1100

M Kanekiyo, BuW, MG Joyce, G Meng, JR Whittle
  • doi: 10.1016/j.cell.2015.07
  • 2015
VIEW 1 EXCERPT